“Nothing about us, without us, is for us.”
– The spirit of REACH continues to inspire progress.
The REACH EAP Strategic Advisory Group (SAG) convened for an internal, full-day session on 5 December 2024 ahead of the EAP Winter Meeting in Brussels. The internal discussion brought together 15 participants, setting the stage for further progress on the group’s initiatives.
The following day, the EAP Winter Meeting welcomed over 80 attendees, underscoring the broad engagement and shared interest in advancing paediatric healthcare across Europe.
Focus on the Mi-CARE Project
The centrepiece of the REACH discussions was the Mi-CARE Project, the group’s inaugural initiative in partnership with the James Lind Alliance (JLA). This ambitious project aims to identify and prioritise unanswered research questions related to paediatric migrant health in Europe, ensuring that the concerns of migrant children, adolescents, caregivers, and healthcare professionals are heard and acted upon.
Follow the link below to participate in the MiCare Survey! Help us Gather 300 responses before 31 Dec 2024!!
Key Discussions and Outcomes
The internal session on 5 Dec 2024 covered:
Progress of the Mi-CARE Survey:
Preliminary Data Analysis:
Collaborative Strategies:
Future Planning:
A Vision for Equitable Healthcare
The REACH Dream for 2025
Dr. Julia Brandenberger, Chair of REACH SAG emphasised the importance of collective effort in achieving equitable healthcare for migrant children and adolescents.
The Mi-CARE project is a pioneering step in breaking down research silos and fostering a truly inclusive healthcare agenda driven by the voices of those it serves.
To participate in the Mi-CARE survey or learn more, visit the EAP website. Together, we can make a lasting impact on the health and well-being of migrant families across Europe.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.